Stocks · News reference
Anika Therapeutics Q2 Adj. EPS $0.42 May Not Compare To $(0.08) Estimate, Sales $32.610M Beat $29.215M Estimate
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 29, 2026, 11:08 AM
- Checked
- Jul 29, 2026, 11:07 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Anika Therapeutics shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY26 sales guidance with its midpoint above estimates.
Read original at benzinga8-K filing — Anika Therapeutics, Inc. (ANIK)
Filed: 2026-07-29 AccNo: 0001171843-26-004977 Size: 408 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarAnika Therapeutics Raises FY2026 Sales Guidance from $114.000M-$122.500M to $118.460M-$124.101M vs $118.612M Est
Read original at benzinga